Radiation-induced cholecystitis after hepatic radioembolization: do we need to take precautionary measures?

Journal of Vascular and Interventional Radiology

Volumn 25, Issue 11, 2014, Pages 1717-1723

  Prince, Jip F ^a   Van Den Hoven, Andor F ^a   Van Den Bosch, Maurice A A J ^a   Elschot, Mattijs ^a   De Jong, Hugo W A M ^a   Lam, Marnix G E H ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIEMETIC AGENT; FLUORODEOXYGLUCOSE F 18; HOLMIUM; HOLMIUM 166; MACROSALB TC 99M; MICROSPHERE; UNCLASSIFIED DRUG; RADIOPHARMACEUTICAL AGENT;

ABDOMINAL PAIN; ADULT; ANGIOGRAPHY; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CHOLECYSTITIS; COIL EMBOLIZATION; COLORECTAL CANCER; FOLLOW UP; GALLBLADDER; HEPATIC ARTERY; HUMAN; LIVER METASTASIS; MALE; MIDDLE AGED; NAUSEA AND VOMITING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIATION DOSE REDUCTION; RADIATION INJURY; RADIOACTIVITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMIC THERAPY; VASCULARIZATION; ADVERSE EFFECTS; BRACHYTHERAPY; CHOLECYSTOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; LIVER; LIVER NEOPLASMS; PROCEDURES; RADIATION DOSE; RADIATION INJURIES; RADIATION RESPONSE; RADIOGRAPHY; SCINTISCANNING; SECONDARY; TREATMENT OUTCOME;

BRACHYTHERAPY; CHOLECYSTITIS; CHOLECYSTOGRAPHY; FOLLOW-UP STUDIES; GALLBLADDER; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; RADIATION INJURIES; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; TECHNETIUM TC 99M AGGREGATED ALBUMIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84928106806     PISSN: 10510443     EISSN: 15357732     Source Type: Journal    
DOI: 10.1016/j.jvir.2014.06.024     Document Type: Article

References (34)

1. Riaz A, Lewandowski RJ, Kulik LM, et al. Complications following radioembolization with yttrium-90 microspheres: A comprehensive literature review. J Vasc Interv Radiol 2009; 20:1121-1130.
2. Ahmadzadehfar H, Sabet A, Biermann K, et al. The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment. J Nucl Med 2010; 51:1206-1212.
3. van den Hoven AF, Prince JF, Samim M, et al. Posttreatment PET-CT- confirmed intrahepatic radioembolization performed without coil embolization, by using the antireflux Surefire Infusion System. Cardiovasc Intervent Radiol 2014; 37:523-528.
4. Hamoui N, Minocha J, Memon K, et al. Prophylactic embolization of the gastroduodenal and right gastric arteries is not routinely necessary before radioembolization with glass microspheres. J Vasc Interv Radiol 2013; 24: 1743-1745.
5. Atassi B, Bangash AK, Lewandowski RJ, et al. Biliary sequelae following radioembolization with Yttrium-90 microspheres. J Vasc Interv Radiol 2008; 19:691-697.
6. Hickey R, Lewandowski RJ. Hepatic radioembolization complicated by radiation cholecystitis. Semin Intervent Radiol 2011; 28:230-233.
7. Jakobs TF, Hoffmann RT, Dehm K, et al. Hepatic yttrium-90 radio- embolization of chemotherapy-refractory colorectal cancer liver metasta- ses. J Vasc Interv Radiol 2008; 19:1187-1195.
8. Miller FH, Keppke AL, Reddy D, et al. Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET. AJR Am J Roentgenol 2007; 188:776-783.
9. Sato KT, Lewandowski RJ, Mulcahy MF, et al. Unresectable chemo- refractory liver metastases: radioembolization with 90Y microspheres- safety, efficacy, and survival. Radiology 2008; 247:507-515.
10. McWilliams JP, Kee ST, Loh CT, Lee EW, Liu DM. Prophylactic embolization of the cystic artery before radioembolization: feasibility, safety, and outcomes. Cardiovasc Intervent Radiol 2011; 34:786-792.
11. Wee E, Chang WS, Oo AM, Shuter B, Lim SG. W1780 Yttrium-90 SIRT for the treatment of unresectable hepatocellular carcinoma: outcomes of an Asian cohort. Gastroenterology 2009; 136:A-860.
12. Paprottka PM, Jakobs TF, Reiser MF, Hoffmann RT. Practical vascular anatomy in the preparation of radioembolization. Cardiovasc Intervent Radiol 2012; 35:454-462.
13. Powerski MJ, Scheurig-Munkler C, Banzer J, Schnapauff D, Hamm B, Gebauer B. Clinical practice in radioembolization of hepatic malignancies: A survey among interventional centers in Europe. Eur J Radiol 2012; 81:e804-e811.
14. Theysohn JM, Muller S, Schlaak JF, et al. Selective internal radiotherapy (SIRT) of hepatic tumors: how to deal with the cystic artery. Cardiovasc Intervent Radiol 2013; 36:1015-1022.
15. ACR-ASTRO-SIR Practice Guideline for Radioembolization with Micro- sphere Brachytherapy Device (RMDB) for Treatment of Liver Malignancies. Available at http://www.acr.org/-/media/D8086059B5F541E9B64E55D68A71693B.pdf. Accessed November 4, 2013.
16. Dezarn WA, Cessna JT, DeWerd LA, et al. Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachy- Dherapy in the treatment of hepatic malignancies. Med Phys 2011; 38: 4824-4845.
17. Giammarile F, Bodei L, Chiesa C, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging 2011; 38: 1393-1406.
18. Lewandowski RJ, Sato KT, Atassi B, et al. Radioembolization with 90Y microspheres: Angiographic and technical considerations. Cardiovasc Intervent Radiol 2007; 30:571-592.
19. Mahnken AH, Spreafico C, Maleux G, Helmberger T, Jakobs TF. Standards of practice in transarterial radioembolization. Cardiovasc Intervent Radiol 2013; 36:613-622.
20. Smits ML, Nijsen JF, van den Bosch MA, et al. Holmium-166 radio- embolisation in patients with unresectable, chemorefractory liver meta- stases (HEPAR trial): A phase 1, dose-escalation study. Lancet Oncol 2012; 13:1025-1034.
21. Smits ML, Elschot M, van den Bosch MA, et al. In vivo dosimetry based on SPECT and MR imaging of 166Ho-microspheres for treatment of liver malignancies. J Nucl Med 2013; 54:2093-2100.
22. Elschot M, Smits ML, Nijsen JF, et al. Quantitative Monte Carlo-based holmium-166 SPECT reconstruction. Med Phys 2013; 40:112502.
23. Smits ML, van den Hoven AF, Rosenbaum CE, et al. Clinical and laboratory toxicity after intra-arterial radioembolization with (90)y- microspheres for unresectable liver metastases. PloS One 2013; 8: e69448.
24. Atassi B, Bangash AK, Bahrani A, et al. Multimodality imaging following 90Y radioembolization: A comprehensive review and pictorial essay. Radiographics 2008; 28:81-99.
25. Garin E, Rolland Y, Boucher E, et al. First experience of hepatic radioembolization using microspheres labelled with yttrium-90 (Thera- Sphere): practical aspects concerning its implementation. Eur J Nucl Med Mol Imaging 2010; 37:453-461.
26. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13:176-181.
27. Peterson JL, Vallow LA, Johnson DW, et al. Complications after (90)Y microsphere radioembolization for unresectable hepatic tumors: An evaluation of 112 patients. Brachytherapy 2013; 12:573-579.
28. Bester L, Feitelson S, Milner B, Chua TC, Morris DL. Impact of prior hepatectomy on the safety and efficacy of radioembolization with yttrium-90 microspheres for patients with unresectable liver tumors. Am J Clin Oncol In press; available online February 5, 2013.
29. Bester L, Meteling B, Pocock N, et al. Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. J Vasc Interv Radiol 2012; 23:96-105.
30. Cianni R, Urigo C, Notarianni E, et al. Selective internal radiation therapy with SIR-spheres for the treatment of unresectable colorectal hepatic metastases. Cardiovasc Intervent Radiol 2009; 32:1179-1186.
31. Jiao LR, Szyszko T, Al-Nahhas A, et al. Clinical and imaging experience with yttrium-90 microspheres in the management of unresectable liver tumours. Eur J Surg Oncol 2007; 33:597-602.
32. Cianni R, Urigo C, Notarianni E, et al. Radioembolisation using yttrium 90 (Y-90) in patients affected by unresectable hepatic metastases. Radiol Med 2010; 115:619-633.
33. Basciano CA, Kleinstreuer C, Kennedy AS, Dezarn WA, Childress E. Computer modeling of controlled microsphere release and targeting in a representative hepatic artery system. Ann Biomed Eng 2010; 38: 1862-1879.
34. Kennedy AS, Kleinstreuer C, Basciano CA, Dezarn WA. Computer modeling of yttrium-90-microsphere transport in the hepatic arterial tree to improve clinical outcomes. Int J Radiat Oncol Biol Phys 2010; 76: 631-637.